Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.06 +0.16 (+1.11%)
Streaming Delayed Price Updated: 2:17 PM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial ↗
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Takeda Provides Update on EXKIVITY® (mobocertinib)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So. ↗
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that... 
Via Benzinga
Topics Economy
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗
 
Via Benzinga
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris ↗
Via The Motley Fool
News headline image
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now ↗
These two high-yield dividend stocks are attractive buys right now. 
Via The Motley Fool
News headline image
How Is The Market Feeling About Takeda Pharmaceutical? ↗
 
Via Benzinga
News headline image
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
Morphic Therapeutic's Stock Plunges On Monday - Here's Why? ↗
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results... 
Via Benzinga
News headline image
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days ↗
The company is working on a treatment for ulcerative colitis. But competitive questions linger. 
Via Investor's Business Daily
News headline image
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Top 4 Health Care Stocks That Should Keep You Up At Night ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now? ↗
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to... 
Via Benzinga
News headline image
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan ↗
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the... 
Via Benzinga
News headline image
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan ↗
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and  
Via Benzinga
News headline image
Why Are Poseida Therapeutics Shares Moving Higher Today? ↗
Poseida Therapeutics Inc (NASDAQ: PSTX) shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc (OTC: ALMPY) (OTC: 
Via Benzinga
News headline image
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories ↗
Wall Street Journal 
Via Benzinga
News headline image
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
News headline image
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.